Luiza Doro Pereira

Luiza Doro Pereira

Auto-generated profile, based on publicly available information

Luiza Doro Pereira

Division of Gynecologic Oncology, Department of OB/GYN, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JHJustine Habault
Justine Habault
JSJeffrey A. Schneider
Jeffrey A. Schneider
SHSusan Ha
Susan Ha
RRRachel Ruoff
Rachel Ruoff
LPLuiza D. Doro Pereira
Luiza D. Doro Pereira
MGMichael J. Garabedian
Michael J. Garabedian
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.

1 February 2025 in Cancer Research Communications
Verified
Journal Article
Open access
LPLuiza Doro Pereira
Luiza Doro Pereira
MWMonica Wielgos-Bonvallet
Monica Wielgos-Bonvallet
SMSelim Misirlioglu
Selim Misirlioglu
AKAlireza Khodadadi-Jamayran
Alireza Khodadadi-Jamayran
PJPetar Jelinic
Petar Jelinic
DLDouglas A Levine
Douglas A Levine
Immune checkpoint inhibitors (ICI) have revolutionized treatment for several tumor indications without demonstrated benefit for patients with ovarian cancer. To improve the therapeutic ratio of ICIs in patients with ovarian cancer, several different clinical trials are testing combinations with poly(ADP-ribose) polymerase (PARP) inhibitors. Comparing the immunomodulatory effects of clinically advanced PARP inhibitors (PARPi) may help to identify the best partner to combine with ICIs. We examined the treatment effect of talazoparib (a PARP trapper) and veliparib (a solely PARP enzymatic inhibitor) in homologous recombination deficient (HRD) and homologous recombination proficient high-grade serous tubo-ovarian carcinoma (HGSC) cell lines on immune-related gene expression. We discovered and validated that CXCL8, IL-6, and TNF gene expression were upregulated after talazoparib treatment in both OVCAR3 (HRD) and CAOV3 homologous recombination proficient HGSC cell lines. In contrast, veliparib treatment slightly elevated similar genes exclusively in an HRD HGSC cell line model. We expanded these studies to include olaparib, a PARP trapper less potent than talazoparib, and found effects specific to COV361 (BRCA1 mutant) and OVCAR8 (BRCA1 methylated) HGSC cells but not all HRD HGSC cell lines. Our studies also identified differences among PARP trappers versus veliparib on augmenting CXCL10 expression. Finally, we show that talazoparib modulates the CXCL10 response in cGAS-defective cell lines, independent of the cGAS-STING pathway. These mechanistic studies advance our understanding of how different PARPis affect the immune system in various genetic backgrounds. Significance: This work highlights how different PARPis, especially talazoparib, modulate immune-related gene expression in ovarian cancer cells, independent of the cGAS-STING pathway. These findings may improve our understanding of how different PARPis affect the immune system in various genetic backgrounds.

7 November 2025
Verified
Other
Open access
LPLuiza Doro Pereira
Luiza Doro Pereira
MWMonica Wielgos-Bonvallet
Monica Wielgos-Bonvallet
SMSelim Misirlioglu
Selim Misirlioglu
AKAlireza Khodadadi-Jamayran
Alireza Khodadadi-Jamayran
PJPetar Jelinic
Petar Jelinic
DLDouglas A Levine
Douglas A Levine
Supplementary Table 1 shows enriched gene sets upregulated in CAOV3 cells treated with talazoparib.

7 November 2025
Verified
Other
Open access
LPLuiza Doro Pereira
Luiza Doro Pereira
MWMonica Wielgos-Bonvallet
Monica Wielgos-Bonvallet
SMSelim Misirlioglu
Selim Misirlioglu
AKAlireza Khodadadi-Jamayran
Alireza Khodadadi-Jamayran
PJPetar Jelinic
Petar Jelinic
DLDouglas A Levine
Douglas A Levine
Supplementary Table 2 shows enriched gene sets upregulated in OVCAR3 cells treated with talazoparib.

7 November 2025
Verified
Other
Open access
LPLuiza Doro Pereira
Luiza Doro Pereira
MWMonica Wielgos-Bonvallet
Monica Wielgos-Bonvallet
SMSelim Misirlioglu
Selim Misirlioglu
AKAlireza Khodadadi-Jamayran
Alireza Khodadadi-Jamayran
PJPetar Jelinic
Petar Jelinic
DLDouglas A Levine
Douglas A Levine
Supplementary Table 4 shows enriched gene sets upregulated in CAOV3 cells treated with veliparib .

19 June 2026
Verified
Other
Open access
JHJustine Habault
Justine Habault
JSJeffrey A. Schneider
Jeffrey A. Schneider
SHSusan Ha
Susan Ha
RRRachel Ruoff
Rachel Ruoff
LPLuiza D. Pereira
Luiza D. Pereira
MGMichael J. Garabedian
Michael J. Garabedian
Chemical structures and IC50 of the multivalent ethisterone-peptoid conjugate